NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	24/06/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : AIN457 INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Subcutaneous Injection

Outcome(s)

Primary Outcome	Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 12 weeks ]
Secondary Outcome	Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 52 weeks ]

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	-Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
Exclude criteria	-Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). -Current drug-induced psoriasis. -Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.